Abstract
An improved HPLC based method to assay the oral active iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1, CP20) in serum and urine is described. The L1 peak has been well separated from other endogenous compounds, allowing the exact determination of the drug in both biological fluids. Moreover urinary iron excretion due to L1 therapy has been monitored by measuring urine Fe-(L1)3 complex concentrations using reverse phase HPLC and subsequent detection at 450 nm. In patients and normal volunteers receiving this drug there is a good correlation between urine iron excretion measured by AAS and by the HPLC based method.
Similar content being viewed by others
References
Hershko C (1993) Lancet 341:1088–1089
Hider RC, Kontoghiorghes GJ, Silver J (1982) U.K. Patent: GB-2118176
Kontoghiorghes GJ, Aldouri MA, Sheppard L, Hoffbrand AV (1987) Lancet i: 1294–1295
Kontoghiorghes GJ, Goddard JG, Bartlett AN, Sheppard L (1990) Clin Pharmacol Ther 48 (3):255–261
Olivieri NF, Koren G, Hermann Ch, Bentur Y, Chung D, Klein J, St Louis P, Freedman MH, McClelland RA, Templeton DM (1990) Lancet 336:1275–1279
Barlett AN, Hoffbrand AV, Kontoghiorghes GJ (1990) Br J Haematol 76:301–304
Al-Refaie FN, Wonke B, Hoffbrand AV, Wickens DG, Nortey P, Kontoghiorghes GJ (1992) Blood 80 (3):593–599
Fassos FF, Klein J, Fernandes D, Matsui D, Olivieri NF, Koren G (1994) Clin Pharmacol Ther 55:70–75
Hoffbrand AV, Kontoghiorghes GJ (1992) Drugs of today 28 (suppl A):149–155
Goddard JG, Kontoghiorghes GJ (1990) Clin Chem 36/1:5–8
Kontoghiorghes GJ, Sheppard L (1987) Inorganica Chimica Acta 136:L11-L12
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dresow, B., Fischer, R., Janka, G.E. et al. HPLC-based measurement of the chelator 1,2-dimethyl-3-hydroxy-pyrid-4-one (L1) and its iron complex for pharmacokinetic studies in humans. Fresenius J Anal Chem 352, 562–564 (1995). https://doi.org/10.1007/BF00323074
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00323074